Allos Therapeutics seeks funds for anticancer candidate
21 July 2009
Christopher Spillane
Please Login to read the full article.
21 July 2009
Christopher Spillane
christopher.spillane@informausa.com
Allos Therapeutics plans to raise as much as $150 million in a common offering of up to 26.1 million shares. The firm will use the proceeds to advance its only clinical candidate, the anticancer agent pralatrexate, towards a potential commercial launch and for general corporate purposes.
Pralatrexate...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Mundipharma pays Allos $50 million up front for ex-US rights to lymphoma drug
- Spectrum ready-to-use Fusilev wins US FDA OK
- Spectrum raises $25M as it builds on Zevalin, Fusilev franchises to fund oncology pipeline
- Positive Phase II data for Teva/CureTech's DLBCL antibody treatment
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
